Sun Pharmaceutical Industries Ltd. closed 12.97% below its 52-week high of 1,960.20 rupees, which the company achieved on ...

Sun Pharmaceutical Industries Ltd. closed 10.79% short of its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Inozyme Pharma (INZY – Research Report), with a price target of $11.00. The company’s shares ...

RBC Capital analyst Gregory Renza maintained a Buy rating on aTyr Pharma (ATYR – Research Report) yesterday and set a price target of $16.00. The company’s shares closed yesterday at $3.99.

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...

The New Jersey Economic Development Authority (NJEDA) Board approved tax credits under the Emerge Program to support Sun Pharmaceutical Industries Inc.’s (Sun Pharma) plan to open a new US ...

Produce high-quality, injectable drug delivery systems with the Thermo Scientific™ Pharma mini Implant Line. This automated end-to-end solution meets cGMP and FDA requirements. Accurate dosing ...

Pharmaceutical Refrigerator MED-125 from Kirsch Pharmaceutical Refrigerator MED-85 from Kirsch High Credibility: This website adheres to all nine standards of credibility and transparency.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Sun Pharma's Q3FY25 net profit rose 15% YoY to ₹2,903 crore, driven by strong domestic and global specialty sales. Revenue grew 10.5%, while EBITDA surged 15.3% with improved margins. The company ...